It interacts with the C-terminus of PD-L1, deubiquitinates PD-L1 (86), and inhibits its degradation via the USP22-CSN5-PD-L1 axis (87), which is closely associated with the prognosis of HCC (88). The gene discussed is USP22; the disease is hepatocellular carcinoma.